In recent years, many studies found that KRAS mutation was associated with the recurrence [49–51] and with survival prognosis in various types of cancer [32,35][38], but several studies suggested that KRAS mutation in cfDNA was not associated with survival outcome of patients with pancreatic, lung or colon cancer [14,25,33]. The gene discussed is KRAS; the disease is cancer.